Expect margins of major pharma firms to improve: Pharma Analysts
PUBLISHED ON: May 10, 2012 | Duration: 10 min, 29 sec
Cipla's sensitivity is highest to the depreciation of the rupee as it does not hedge. Praful Bohra, Pharma Analyst at Nirmal Bang Institutional Equities and Siddhant Khandekar, Senior Pharma Analyst at ICICI Securities said that Cipla's margin outlook has improved for FY13. They expect margins of Cipla, Lupin and Dr. Reddy's Lab to improve in the fourth quarter.